Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cara Therapeutics, Inc.    CARA

CARA THERAPEUTICS, INC.

(CARA)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
15.33(c) 14.99(c) 15.16(c) 15.05(c) 14.95(c) Last
363 142 358 891 240 102 261 066 154 221 Volume
-3.77% -2.22% +1.13% -0.73% -0.66% Change
More quotes
Financials (USD)
Sales 2020 65,1 M - -
Net income 2020 -53,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -10,3x
Yield 2020 -
Sales 2021 28,4 M - -
Net income 2021 -90,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,56x
Yield 2021 -
Capitalization 745 M 745 M -
Capi. / Sales 2020 11,4x
Capi. / Sales 2021 26,2x
Nbr of Employees 76
Free-Float 83,9%
More Financials
Company
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of... 
More about the company
All news about CARA THERAPEUTICS, INC.
11/11CARA THERAPEUTICS : to Present at Multiple Upcoming Investor Conferences
AQ
11/11Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
GL
11/09CARA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
11/09CARA : 3Q Earnings Snapshot
AQ
11/09CARA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financi..
AQ
11/09CARA THERAPEUTICS : Reports Third Quarter 2020 Financial Results
AQ
11/09Cara Therapeutics Reports Third Quarter 2020 Financial Results
GL
11/02CARA THERAPEUTICS : to Announce Third Quarter 2020 Financial Results on November..
AQ
11/02Cara Therapeutics to Announce Third Quarter 2020 Financial Results on Novembe..
GL
10/27CARA THERAPEUTICS : SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milest..
PR
10/22CARA THERAPEUTICS : Announces Presentation at American Society of Nephrology Kid..
AQ
10/21CARA THERAPEUTICS : Announces Presentation at American Society of Nephrology Kid..
AQ
10/21Cara Therapeutics Announces Presentation at American Society of Nephrology Ki..
GL
10/21CARA THERAPEUTICS : Vifor pharma and cara therapeutics sign us license agreement..
AQ
10/21Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva t..
AQ
More news
News in other languages on CARA THERAPEUTICS, INC.
10/20Bourse Zurich: les indices terminent en ordre dispersé
10/20Résumé des principales informations économiques du mardi 20 octobre 2020
10/20Bourse Zurich: Logitech entraîne les indices secondaires
10/20AKTIEN IM FOKUS : FMC unter Chartunterstützung - Fresenius bleiben schwach
10/20Vifor injecte 150 millions de dollars de plus pour le Korsuva de Cara aux USA
More news
Chart CARA THERAPEUTICS, INC.
Duration : Period :
Cara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 32,63 $
Last Close Price 14,95 $
Spread / Highest target 168%
Spread / Average Target 118%
Spread / Lowest Target 20,4%
EPS Revisions
Managers
NameTitle
Derek T. Chalmers President, Chief Executive Officer & Director
Thomas Reilly Chief Financial & Accounting Officer
Frèdèrique Menzaghi Chief Scientific Officer, Senior VP-R&D
Joana Goncalves Chief Medical Officer
Martin A. Vogelbaum Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARA THERAPEUTICS, INC.-7.20%745
IQVIA HOLDINGS INC.9.26%32 365
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 070
PRA HEALTH SCIENCES, INC.-0.14%7 120
SYNEOS HEALTH, INC.12.08%6 932
NOVAVAX, INC.2,477.89%6 427